GoldenGolden

Triplet Therapeutics

A therapeutics company developing siRNA and ASO therapeutics that target repeat expansion disorders such as Huntington’s disease, myotonic dystrophy and spinocerebellar ataxias

Triplet Therapeutics is a therapeutics company that is developing transformative therapies for the treatment of repeat expansion disorders at their source. The company's mission is to prevent repeat expansion disorders and ensure a future for patients.

Triplet is developing a different treatment for repeat expansion disorders, including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy and, by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression.

The company comprises of a team with years of expertise in drug discovery, clinical research, genetics, and operations. It is supported by a syndicate of investors who share the company's commitment of transforming the lives of patients and families who are affected by repeat expansion disorders.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 27, 2021
BioSpace
TTX-3360, an antisense oligonucleotide delivered by intracerebroventricular (ICV) injection, targets MSH3, a component of the DNA Damage Response pathway
BioSpace
November 17, 2020
BioSpace
Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders, announced the appointments of Kathy Biberstein, J.D., and Stephen Webster to its board of directors.
May 27, 2020
BioSpace
Triplet Therapeutics Initiates SHIELD HD Natural History Study of Huntington's Disease - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.